SCHEMBL14008933

SCHEMBL14008933

COc1ccc(C(=O)Nc2ccc(C(=O)Nc3ccc(-n4cncn4)cc3)s2)c(C)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.45
▸ ICAM1 P05362 1/20 0.41
▸ SELE P16581 1/20 0.41
▸ VCAM1 P19320 1/20 0.41
▸ LMNA P02545 3/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ NPC1 O15118 3/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ SNCA P37840 1/20 0.40
▸ F10 P00742 2/20 0.40
▸ JAK2 O60674 1/20 0.39
▸ TYK2 P29597 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ CTSL P07711 1/20 0.38
▸ CTSS P25774 1/20 0.38
▸ CTSK P43235 1/20 0.38
▸ F2 P00734 1/20 0.38
▸ PLAU P00749 1/20 0.38
▸ PLAT P00750 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14009082 0.88 MAPT (0.53) MAPTLMNASMN1; SMN2KDM4ENPC1
SCHEMBL14008981 0.87 CYP1A2 (0.46) MAPTLMNAKDM4ENPC1RAB9A
SCHEMBL14009015 0.85 MAPT (0.46) MAPTICAM1SELEVCAM1LMNA
SCHEMBL14009050 0.85 MAPT (0.50) MAPTLMNASMN1; SMN2KDM4ENPC1
SCHEMBL14008925 0.84 SMN1; SMN2 (0.54) MAPTICAM1SELEVCAM1LMNA
SCHEMBL14009071 0.81 MAPT (0.42) MAPTICAM1SELEVCAM1LMNA
SCHEMBL14009303 0.80 MAPT (0.45) MAPTLMNASMN1; SMN2NPC1RAB9A
SCHEMBL14009219 0.80 KMT2A (0.53) MAPTLMNASMN1; SMN2KDM4ENPC1
SCHEMBL14009111 0.80 F10 (0.49) MAPTICAM1SELEVCAM1LMNA
SCHEMBL14009096 0.80 F10 (0.49) MAPTICAM1SELEVCAM1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7446195-B2 High affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION (US) 2008-11-04 — — US disclosed
US-7446195-B2 High affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION (US) 2008-11-04 — — US disclosed
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION 2007-02-22 — — US disclosed
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION 2007-02-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands CDKL2, CDK2, CDKL1 MAPT 2145/4885ICAM1 4295/4885SELE 4030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback